This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The outcomes derived from the APPROACH database were: the death rate within 7 days after an initial PCI; the rate of repeat catheterisation for restenosis within 12 months after index PCI with or without the revascularisation procedure; the death rate within 6 months; the death rate within 30 days after patients received CABG or repeat PCI, and for those without a revascularisation procedure; the subsequent mortality rate; and the EQ-5D utility score for an event and for an event-free health state.
The outcome derived from the review of the literature was the relative risk of clinical restenosis of sirolimus-eluting stents in comparison with conventional stents.
Study designs and other criteria for inclusion in the review
Only RCTs were included in the review of the literature to determine the efficacy of sirolimus-eluting stents.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The APPROACH database was used to derive all outcome data. In addition, four RCTs were included in the review to determine the efficacy of sirolimus-eluting stents.
The authors did not report that a systematic review of the literature was undertaken to identify all relevant research and minimise biases. However, the authors included four RCTs to derive effectiveness estimates, with these being appropriately combined in a meta-analysis. Further, the authors investigated differences between the four trials using appropriate statistical techniques, and found the studies to be homogeneous. The authors also supplemented data from the literature with their own assumptions, which were appropriately tested in the sensitivity analysis.
Validity of estimate of measure of benefit
The estimation of benefits (QALYs) was modelled using a Markov model, which was appropriate. The utility scores were obtained using the EQ-5D and the cohort of patients undertaking the APPROACH study. The use of QALYs facilitates comparisons across different health care programmes.
Validity of estimate of costs
All the categories of cost relevant to the health care service perspective adopted were included in the analysis, as were all relevant cost for each category. The costs and the quantities were not reported separately, which will limit the generalisability of the authors' results. The costs were derived from 1,812 patients in the APPROACH database who underwent an initial PCI. Appropriate sensitivity analyses of the prices were conducted. Since the costs were incurred over the lifetime of the patient, discounting was necessary and was appropriately performed. The authors inflated the prices using inflation indices. However, it was unclear if the inflation index used was a general one, or a health care one. This is important as health care prices tend to increase faster than general prices. The price year was reported, which will aid any future inflation exercises.
